Do you want to read an article? Please log in or register.
Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab
Multiple Myeloma (MM)
Related content
Multiple Myeloma (MM)
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
Blood Cancer J
Cheema H, Shrestha A, Naqvi S, Muttineni S, Dronavalli S, Alrawabdeh J, Alzu'bi M, Schinke CD, Thanendrarajan S, Shaughnessy JD Jr, Zhan F, Zangari M, van Rhee F, Hadidi SA
doi: 10.1038/s41408-026-01484-0
CHICAGO 2026
Multiple Myeloma (MM)
MajesTEC-9: Teclistamab significantly improves survival outcomes in patients with RRMM
RECOMMENDED
Further Publications
Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants for Extended Secondary Venous Thromboembolism Prophylaxis in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Trials
★ 2
Recommended by
Dr Andreas Müller, Faculty Member
Am J Hematol
Mahmoud A, Eltaher B, Shah P, Vengilote R, Mostafa M, Afzal A, Sanfilippo KM
doi: 10.1002/ajh.70090
EHA 2025
Multiple Myeloma (MM)
RedirecTT-1: Deep and durable responses with talquetamab plus teclistamab in RRMM patients with extramedullary disease
Multiple Myeloma (MM)
Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab
Haematologica
Lancman G, Sastow D, Aslanova M, Moshier E, Cho HJ, Jagannath S, Parekh S, Richard S, Richter J, Rodriguez C, Rossi A, Sanchez L, Thibaud S, Chari A
doi: 10.3324/haematol.2025.289215
Central Nervous System Tumors
Cumulative dose of chemotherapy and survival outcomes in children with average risk medulloblastoma treated on Children's Oncology Group study ACNS0331
Neuro Oncol
Wright E, Billups C, Rush S, Li Y, Janns A, Michalski JM, Salloum R, de Blank P
doi: 10.1093/neuonc/noag064
Genitourinary Cancer
Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis
Prostate Cancer Prostatic Dis
Saporita I, Calabrese M, Carfi FM, Mogavero A, Puglisi M, Treglia G, Vogl UM, Gillessen S, Pereira Mestre R, Pedrani M, Pecoraro G, Salfi G, Erhart CC, Lin HM, Tortola L, Di Maio M, Tucci M, Buttigliero C, Turco F
doi: 10.1038/s41391-026-01077-9
Genitourinary Cancer
Impact of Intraprostatic Simultaneous Integrated Boost on Long-Term Outcomes in Unfavorable Intermediate-Risk Prostate Cancer Treated With Dose-Escalated Radiotherapy and Short-Term Androgen Deprivation Therapy
Prostate
Onal C, Elmali A, Demirhan B, Senturk E, Erpolat P, Guler OC
doi: 10.1002/pros.70167
Multiple Myeloma (MM)
Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant
Br J Haematol
Venkatesh P, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, Giri S, Godby KN, Silbermann RW, Mikhail FM, Huls F, Reddy V, Costa LJ, Bal S
doi: 10.1111/bjh.70359